Identification of inflammasome signatures for the prediction of successful treatment-free remission (TFR) in chronic Myeloid Leukaemia

鉴定炎症体特征以预测慢性粒细胞白血病成功的无治疗缓解（TFR）

• 批准号: 2766165
• 金额: --
• 依托单位: University of Glasgow
• 依托单位国家: 英国
• 项目类别: Studentship
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=studentship-2766165
• 关键词: Identification; inflammasome; signatures; prediction; successful

Studentship strategic priority area: Stem Cell ScienceAbstract: Chronic myeloid leukaemia (CML) is a haematological cancer characterised by expansion of haematopoietic stem cells and unregulated production of granulocytic blood cells. The prognosis of patients with CML has greatly improved over the past 20 years since the introduction of targeted therapies called Tyrosine Kinase Inhibitors (TKIs), with many patients being able to achieve molecular remission and having close to normal life expectancy. However, the lifelong use of TKIs has many physiological, psychological and economic side effects. There is a subset of patients on TKIs, which could potentially stop treatment and achieve treatment-free remission (TFR). These patients are in deep molecular remission however it is not well understood which patients are able to achieve TFR and why. This project will look to identify potential biomarkers that predict which patients are good candidates for TFR. This will be performed using proteomic analysis of bone marrow plasma samples that were obtained from patients who took part in the DESTINY clinical trial. This trial aimed to gradually reduce and eventually stop TKI treatment. Samples at trial entry will be compared for patients who achieved TFR with those who went on to relapse.

摘要：慢性髓系白血病(CML)是一种血液病，其特征是造血干细胞的扩张和粒系血细胞的无序生成。自推出名为酪氨酸激酶抑制剂(TKI)的靶向治疗以来，CML患者的预后在过去20年中有了很大改善，许多患者能够实现分子缓解，并接近正常预期寿命。然而，终身使用TKIs有许多生理、心理和经济副作用。有一部分患者正在接受TKIs治疗，这可能会停止治疗并实现无治疗缓解(TFR)。这些患者处于深度分子缓解期，但目前还不清楚哪些患者能够实现TFR，以及为什么。该项目将寻找潜在的生物标记物来预测哪些患者是TFR的良好候选者。这将通过对参加Destination临床试验的患者的骨髓血浆样本进行蛋白质组学分析来进行。这项试验的目的是逐步减少并最终停止TKI治疗。试验进入时的样本将与实现TFR的患者和后来复发的患者进行比较。